Clinically, breast cancer patients are widely divided into ER+ (Luminal A/Luminal B), HER2+ and triple negative breast cancer (TNBC) subtypes through estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).2, 3. This evidence concerns the gene PGR and triple-negative breast carcinoma.